EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Circadian Use of Glucocorticoids in Rheumatoid Arthritis

Maurizio Cutolo, Alberto Sulli, Theodore Pincus

Neuroimmunomodulation · 2015 · 22 (1-2) · 33-39

DOI: 10.1159/000362733 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuroimmunomodulation, online erschienen am 12.09.2014. Verfasst von Maurizio Cutolo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A clear temporal relationship exists in rheumatoid arthritis (RA) patients between increased nocturnal levels of pro-inflammatory cytokines, such as TNF-α and interleukin (IL)-6, pro-inflammatory hormones (i.e. melatonin, prolactin) and insufficient night production of the anti-inflammatory cortisol (circadian rhythm). Under long-standing chronic stress of disease, insufficient cortisol is available to inhibit an ongoing nocturnal immune/inflammatory reaction. Clinical RA symptoms follow the same circadian rhythm with highest morning severity. Chronotherapy with nighttime glucocorticoid (GC) availability optimizes the treatment of RA patients with low-dose GCs through more efficient targeting of mediators of the immune/inflammatory reaction during the night to be available on arising. Circadian use of low-dose, long-term prednisone, by using night-release formulations (ingested at 10 to 11 p.m.) especially in early RA patients, appears characterized by a significantly superior efficacy on decreasing morning stiffness and IL-6 serum levels, compared to conventional daytime immediate-release prednisone. Shift from medium-dose, immediate-release prednisone (over 7.5-10 mg/day) to night-release formulations GC low-dose, long-term chronotherapy requires a gradual passage, since the hypothalamic-pituitary-adrenal axis of the treated RA patients, potentially altered by a negative feedback induced by the medium/high daily exogenous GC administration, needs time to re-synchronize control of endogenous GC production into a circadian and more physiological nocturnal hormone availability/optimized efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsArthritis, RheumatoidChronobiology DisordersCircadian RhythmGlucocorticoidsHumans

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy.

Zitieren

APA

Cutolo, M., Sulli, A., & Pincus, T. (2015). Circadian Use of Glucocorticoids in Rheumatoid Arthritis. Neuroimmunomodulation, 22(1-2), 33-39. https://doi.org/10.1159/000362733

Vancouver

Cutolo M, Sulli A, Pincus T. Circadian Use of Glucocorticoids in Rheumatoid Arthritis. Neuroimmunomodulation. 2015;22(1-2):33-39. doi:10.1159/000362733

BibTeX
@article{Cutolo2015,
  author = {Cutolo, Maurizio and Sulli, Alberto and Pincus, Theodore},
  title = {Circadian Use of Glucocorticoids in Rheumatoid Arthritis},
  journal = {Neuroimmunomodulation},
  year = {2015},
  volume = {22},
  number = {1-2},
  pages = {33--39},
  doi = {10.1159/000362733}
}
Kostenlos starten →